CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 29 enrolled
Drug / intervention
Continuous glucose monitoring systemother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06533618
NCT06533618N/ACompleted
CompareCT.gov

Characterization of the "Transfusion-dependent Prediabetes" Using Continuous Glucose Monitoring: the Hemoglycare Study

University of Campania Luigi Vanvitelli·interventional·Posted Aug 1, 2024·Updated Aug 6, 2024

In Brief

A clinical study evaluating Continuous glucose monitoring system for Prediabetic State. Completed, enrolled 29 participants across 1 site.

Detailed Summary

Dysglycemia is a frequent finding in transfusion-dependent thalassemia (TDT). The oral glucose tolerance test (OGTT) remains the only validated screening test, but the procedure is complex and time-consuming. Continuous glucose monitoring (CGM) systems are simple to use, and could have a role in the diabetes mellitus diagnosis. This study involved 39 participants (19 cases and 20 healthy controls) using CGM for the analysis of the glucose metrics. Participants resulted negative for diabetes mellitus screening tests. Patients' clinical data were compared with glucose metrics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrediabetic State
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedAug 1, 2024
Enrollment StartJul 1, 2023
Primary CompletionOct 1, 2023
Study CompletionOct 30, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 1.9 years ago

Interventions

Continuous glucose monitoring systemother

All participants (subjects and controls) applied a Medtronic Guardian4 sensor for seven days.